For research use only. Not for therapeutic Use.
Tomaralimab（Cat No.:I042123）is an investigational monoclonal antibody that targets the CD40 receptor, which plays a crucial role in immune system activation and inflammation. By blocking CD40, Tomaralimab aims to modulate immune responses, potentially reducing the activity of harmful immune cells involved in autoimmune diseases and certain cancers. It is being studied in clinical trials for various conditions, including solid tumors and autoimmune diseases like systemic lupus erythematosus (SLE). Early research suggests that Tomaralimab may help regulate immune function, reduce inflammation, and improve patient outcomes, though further studies are needed to confirm its safety and efficacy.
| CAS Number | 1449294-76-1 |
| Purity | ≥95% |
